Predictors of antitumor necrosis factor primary nonresponse and drug durability in pediatric inflammatory bowel disease
Journal of Pediatric Gastroenterology and Nutrition · 2025
DOI: 10.1002/jpn3.70160 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2025. Verfasst von Nicole Davidson und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Nationwide Children's Hospital, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Infliximab, Adalimumab, Inflammatory Bowel Diseases, Tumor Necrosis Factor-alpha. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, Nationwide Children's Hospital Foundation.
Abstract (Originalsprache)
Objectives
Antitumor necrosis factor (anti‐TNF) therapies are first‐line therapies for children with inflammatory bowel disease (IBD) (Crohn's disease [CD], ulcerative colitis [UC] and IBD‐unclassified [IBD‐U]). Limited studies describing anti‐TNFs durability and loss of response in children. This study evaluates predictors of primary Nonresponse and 3‐year drug durability in children with IBD.
Methods
This was a single‐center retrospective review of patients with IBD less than 18 years old who initiated anti‐TNF (infliximab or adalimumab) from January 1, 2014, to December 31, 2019. Clinical and laboratory data were recorded at the time of anti‐TNF initiation, 14 weeks, 12 months, and 3 years. Predictors of primary nonresponse (discontinuation within 14 weeks) and durability were assessed.
Results
A total of 456 patients initiated anti‐TNF therapy (183 adalimumab and 273 infliximab). Thirty‐seven (8%) patients were primary nonresponders. The 3‐year drug durability for both therapies was >70%. Among patients with CD, the 3‐year durability was >75% for both therapies. The 3‐year durability with UC/IBD‐U was 37% for adalimumab and 56% for infliximab. Predictors of primary nonresponse were an erythrocyte sedimentation rate > 55 mm/h in CD on infliximab, and baseline albumin
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Nationwide Children's Hospital, Columbus, Ohio, USA.
- Division of Pediatric Gastroenterology, Hepatology and Nutrition, Geisinger Janet Weis Children's Hospital, Danville, Pennsylvania, USA.
- Department of Biobehavioral Health, College of Health and Human Development, The Pennsylvania State University, University Park, Pennsylvania, USA.
- Center for Biostatistics, Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, Ohio, USA.
- Biostatistics Resource, Nationwide Children's Hospital, Columbus, Ohio, USA.
- Department of Pediatrics, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
ORCID-Profile: Nicole Davidson, Ross M Maltz
Förderung
- NIA NIH HHS
- Nationwide Children's Hospital Foundation
Zitieren
APA
Davidson, N., Morris, G. A., Wright, M. A., Brock, G., Boyle, B., Dotson, J. L., Michel, H. K., & Maltz, R. M. (2025). Predictors of antitumor necrosis factor primary nonresponse and drug durability in pediatric inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.70160
Vancouver
Davidson N, Morris GA, Wright MA, Brock G, Boyle B, Dotson JL, et al. Predictors of antitumor necrosis factor primary nonresponse and drug durability in pediatric inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition. 2025. doi:10.1002/jpn3.70160
BibTeX
@article{Davidson2025,
author = {Davidson, Nicole and Morris, Grant A and Wright, Molly A and Brock, Guy and Boyle, Brendan and Dotson, Jennifer L and Michel, Hilary K and Maltz, Ross M},
title = {Predictors of antitumor necrosis factor primary nonresponse and drug durability in pediatric inflammatory bowel disease},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2025},
doi = {10.1002/jpn3.70160}
}
EUVIMED